1. Home
  2. RLMD vs MYI Comparison

RLMD vs MYI Comparison

Compare RLMD & MYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$6.93

Market Cap

752.1M

Sector

Health Care

ML Signal

HOLD

Logo Blackrock MuniYield Quality Fund III Inc

MYI

Blackrock MuniYield Quality Fund III Inc

HOLD

Current Price

$10.93

Market Cap

747.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLMD
MYI
Founded
2004
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
752.1M
747.8M
IPO Year
2012
1994

Fundamental Metrics

Financial Performance
Metric
RLMD
MYI
Price
$6.93
$10.93
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$12.40
N/A
AVG Volume (30 Days)
869.6K
252.1K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
45.28
N/A
EPS
N/A
N/A
Revenue
$13,070.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
154.83
N/A
52 Week Low
$0.52
$10.20
52 Week High
$8.00
$11.46

Technical Indicators

Market Signals
Indicator
RLMD
MYI
Relative Strength Index (RSI) 45.89 53.42
Support Level $6.81 $10.88
Resistance Level $7.46 $11.14
Average True Range (ATR) 0.42 0.10
MACD -0.04 0.02
Stochastic Oscillator 50.17 80.23

Price Performance

Historical Comparison
RLMD
MYI

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

About MYI Blackrock MuniYield Quality Fund III Inc

BLACKROCK MUNIYIELD QUALITY FUND III, INC. is an investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes, as is consistent with its investment policies and prudent investment management. The fund invests a majority of its assets in municipal obligations exempt from U.S. federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax). Under normal market conditions, the fund invests mainly in long-term municipal obligations that are investment-grade quality or are considered by the adviser to be of comparable quality at the time of investment. It can also invest directly in such securities or synthetically through the use of derivatives.

Share on Social Networks: